drugset
drugset / Trial / NCT05593250

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

NCT05593250 ↗

Phase 2 Active not recruiting 260 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase 2 study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

Timeline

Start
2023-01-17
Primary completion
2026-12-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1905 Monoclonal antibody — Subcutaneous

Indications

asthma